<DOC>
	<DOC>NCT02865850</DOC>
	<brief_summary>A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of HGB in subjects with DD-CKD.</brief_summary>
	<brief_title>Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)</brief_title>
	<detailed_description>This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction of anemia and maintenance of HGB in subjects with anemia secondary to CKD who have recently initiated dialysis treatment for end-stage renal disease.</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>â‰¥18 years of age Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for endstage kidney disease within 16 weeks prior to Screening Mean Screening hemoglobin &lt;10.0 g/dL Received more than 1 dose of longacting (eg, darbepoetin alfa, methoxy polyethylene glycolepoetin beta [Mircera, C.E.R.A.]) or 2 doses of short acting erythropoiesisstimulating agent (ESA) (eg, recombinant human erythropoietin [rHuEPO]) within 8 weeks prior to Screening. Subjects may not receive any ESA during the Screening period Uncontrolled hypertension Severe heart failure at Screening (New York Heart Association Class IV) Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), urgent coronary revascularization, hospitalization for CHF, or stroke within 12 weeks prior to Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>vadadustat</keyword>
	<keyword>AKB-6548</keyword>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>phase 3</keyword>
	<keyword>cardiovascular</keyword>
</DOC>